Soleno Therapeutics Investors Eligible to Lead Securities Fraud Lawsuit

Law firm announces opportunity for investors to serve as lead plaintiffs in case against biotech company.

Apr. 3, 2026 at 4:53pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of legal documents and a broken syringe on a clean, monochromatic background, symbolizing the legal battle and implications for a biotech company's drug development.A legal battle over alleged securities fraud could have far-reaching consequences for a biotech company's drug pipeline.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, has announced that investors in Soleno Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit against the biotech company. The lawsuit alleges that Soleno Therapeutics made false and misleading statements about the development and regulatory status of its lead drug candidate.

Why it matters

Soleno Therapeutics is a publicly traded biopharmaceutical company focused on developing treatments for rare diseases. The potential securities fraud case could have significant financial and reputational implications for the company if investors are successful in proving the allegations.

The details

The lawsuit alleges that Soleno Therapeutics made false and misleading statements about the development and regulatory status of its lead drug candidate, DCCR, for the treatment of Prader-Willi syndrome. The complaint claims the company misled investors about the likelihood of DCCR receiving FDA approval, which ultimately did not occur.

  • The lawsuit was filed on April 3, 2026.

The players

The Schall Law Firm

A national shareholder rights litigation firm that is announcing the opportunity for Soleno Therapeutics investors to lead the securities fraud class action lawsuit.

Soleno Therapeutics, Inc.

A publicly traded biopharmaceutical company focused on developing treatments for rare diseases, including Prader-Willi syndrome.

Got photos? Submit your photos here. ›

What’s next

The court will set a deadline for investors to come forward and serve as lead plaintiffs in the case.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures from publicly traded biotech companies, especially those developing treatments for rare diseases. Investors will be closely watching the outcome of this case and its potential impact on Soleno Therapeutics.